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The development of highly active antiretroviral therapy (HAART) to treat individuals infected with HIV-1 has dramatically
improved patient outcomes, but HAART still fails to cure the infection. The latent viral reservoir in resting CD4+ T cells is a
major barrier to virus eradication. Elimination of this reservoir requires reactivation of the latent virus. However, strategies
for reactivating HIV-1 through nonspecific T cell activation have clinically unacceptable toxicities. We describe here the
development of what we believe to be a novel in vitro model of HIV-1 latency that we used to search for compounds that
can reverse latency. Human primary CD4+ T cells were transduced with the prosurvival molecule Bcl-2, and the resulting
cells were shown to recapitulate the quiescent state of resting CD4+ T cells in vivo. Using this model system, we screened
small-molecule libraries and identified a compound that reactivated latent HIV-1 without inducing global T cell activation,
5-hydroxynaphthalene-1,4-dione (5HN). Unlike previously described latency-reversing agents, 5HN activated latent HIV-1
through ROS and NF-κB without affecting nuclear factor of activated T cells (NFAT) and PKC, demonstrating that TCR
pathways can be dissected and utilized to purge latent virus. Our study expands the number of classes of latencyreversing therapeutics and demonstrates the utility of this in vitro model for finding strategies to eradicate HIV-1 infection.
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The development of highly active antiretroviral therapy (HAART) to treat individuals infected with HIV-1 has
dramatically improved patient outcomes, but HAART still fails to cure the infection. The latent viral reservoir
in resting CD4+ T cells is a major barrier to virus eradication. Elimination of this reservoir requires reactivation of the latent virus. However, strategies for reactivating HIV-1 through nonspecific T cell activation have
clinically unacceptable toxicities. We describe here the development of what we believe to be a novel in vitro
model of HIV-1 latency that we used to search for compounds that can reverse latency. Human primary CD4+
T cells were transduced with the prosurvival molecule Bcl-2, and the resulting cells were shown to recapitulate the quiescent state of resting CD4+ T cells in vivo. Using this model system, we screened small-molecule
libraries and identified a compound that reactivated latent HIV-1 without inducing global T cell activation,
5-hydroxynaphthalene-1,4-dione (5HN). Unlike previously described latency-reversing agents, 5HN activated
latent HIV-1 through ROS and NF-κB without affecting nuclear factor of activated T cells (NFAT) and PKC,
demonstrating that TCR pathways can be dissected and utilized to purge latent virus. Our study expands the
number of classes of latency-reversing therapeutics and demonstrates the utility of this in vitro model for finding strategies to eradicate HIV-1 infection.
Introduction
Highly active antiretroviral therapy (HAART) can suppress HIV-1
levels in plasma to below the limit of detection of clinical assays
(<50 copies/ml) and reduce the morbidity and mortality of HIV-1
infection. However, HAART alone fails to cure the infection. In particular, HAART leaves latent integrated proviruses unaffected (1,
2). Latent viral genomes reside in a small pool of infected resting
memory CD4+ T cells that constitute a stable viral reservoir. In these
cells, the provirus remains transcriptionally silent as long as the host
cells are in a quiescent state (3–5). This allows the virus to evade host
immune surveillance and rebound quickly following discontinuation of HAART. The remarkable stability of the latent viral reservoir
necessitates lifelong HAART (6). Given the potential for toxicity and
resistance, elimination of the latent reservoir has recently been proposed as a goal worthy of a major scientific effort (7).
Novel therapies targeting the latent reservoir generally involve
reactivation of latent virus (2, 7–13). Expression of viral genes
renders infected cells susceptible to viral cytopathic effects and
immune clearance. Along with HAART, this reactivation strategy could ultimately purge latent virus from infected individuals.
Latent viruses respond to T cell activation signals (10, 12, 14–17).
However, initial attempts to deplete the latent reservoir through
TCR stimulation using anti-CD3 antibodies proved toxic (18, 19).
Conflict of interest: The authors have declared that no conflict of interest exists.
Citation for this article: J. Clin. Invest. 119:3473–3485 (2009). doi:10.1172/JCI39199.
The Journal of Clinical Investigation

The toxicity likely resulted from nonspecific T cell activation and
release of proinflammatory cytokines. Therefore, an ideal treatment
should reactivate latent HIV-1 but avoid global T cell activation.
In the search for activators of latent HIV-1, an important tool
would be an in vitro model that mimics the latent state of HIV-1
in primary resting CD4+ T cells and allows for high-throughput
screening. Some in vitro latency models have been established in
transformed T cell lines (20–22). Although useful, these cell-line
models are fundamentally different from the resting CD4+ T cells
because of their proliferating nature and aberrant signaling pathways. Some primary cell models have been recently developed in
thymocytes or CD4+ T cells (23–26). However, a model that yields
cells in a truly quiescent state in quantities sufficient for highthroughput screening is lacking. Given that HIV-1 preferentially
infects activated CD4+ T cells and that latent viral genomes are
mainly found in resting memory CD4+ T cells (27, 28), it is likely
that HIV-1 latency is established when infected lymphoblasts transit back to a resting state and persist as memory T cells. The low
frequency of the latently infected cells in vivo (5) indicates that the
establishment of latency is inefficient. This is due in part to the
fact that only a small fraction of lymphoblasts normally survive to
become memory cells. Viral cytopathic effects and host immune
clearance may also contribute to the loss of infected cells prior to
the establishment of latency. The inefficiency with which latency
is established in vivo makes the development of an in vitro model
especially challenging.
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Figure 1
Generation of the Bcl-2–transduced primary CD4+ T cells. (A) The structure of the lentiviral vector carrying the human Bcl-2 gene (EB-FLV). The
U3 region of 3′ LTR is deleted (3′ΔLTR) for self inactivation. The expression of human Bcl-2 is driven by EF1α promoter. Ψ, packaging signal;
RRE, rev responsive element; cPPT, central polypurine tract; pEF1α, EF1α promoter. (B) Strategy to generate Bcl-2–transduced primary CD4+
T cells. Primary CD4+ T cells from normal donors were activated and transduced with the Bcl-2–expressing lentiviral vector. Viable cells were
isolated after 3 to 4 weeks of culture in the absence of TCR stimulants or cytokines. (C) Intracellular staining for Bcl-2 with FITC-conjugated
anti–Bcl-2 antibody in freshly isolated CD4+ T cells and Bcl-2–transduced cells. The Bcl-2–transduced cells were maintained in culture without
cytokines for 4 weeks following transduction. Freshly isolated CD4+ T cells stained with FITC-conjugated isotype control antibodies served as
a negative control (purple).

Certain cytokines play a role in T cell survival (29). IL-7 controls the
generation and maintenance of memory CD4+ T cells in vivo (30, 31).
However, IL-7 also reactivates latent HIV-1 (12, 32), and thus using IL-7
to promote the establishment of latency in vitro has been difficult.
The antiapoptotic protein Bcl-2 is a downstream effector of IL-7 signaling and plays an essential role in counteracting the proapoptotic
effects of cytokine withdrawal and maintaining the survival of resting
memory CD4+ T cells (29, 33, 34). The prosurvival effect via Bcl-2 is
the key homeostatic function of IL-7. Overexpression of Bcl-2 largely
restores peripheral T cell homeostasis in the absence of IL-7 receptor
(35, 36), indicating that the prosurvival ability of IL-7 can be decoupled from the proliferative and metabolic effects of IL-7 (37, 38).
Here, we report a strategy for generation of an in vitro HIV-1
latency model in primary CD4+ T cells that takes advantage of the
prosurvival effects of Bcl-2. We developed a method for establishing latent HIV-1 infection in the Bcl-2–transduced primary human
CD4+ T cells. We screened libraries of small molecules and identified what we believe to be a novel compound that efficiently reactivates latent HIV-1 but does not induce global T cell activation.
Our study reveals a new strategy for reactivating latent HIV-1 and
illustrates the application of this in vitro primary cell model in
finding novel agents for the cure of HIV-1 infection.
Results
Transduction of primary human CD4+ T cells with Bcl-2. To allow longterm in vitro survival, we transduced primary CD4+ T cells with
Bcl-2 using a lentiviral vector, EB-FLV, in which Bcl-2 expression is
3474
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driven by the constitutively active promoter of elongation factor 1 α
(EF1α) (Figure 1, A and B). Freshly isolated primary human CD4+
T cells were costimulated with anti-CD3 and anti-CD28 and then
transduced with the Bcl-2–expressing lentiviral vector. Transduced
cells were maintained in the absence of TCR stimulants and exogenous cytokines for more than 3 weeks. Viable cells were then isolated using Ficoll-Hypaque density gradient centrifugation. As
shown in Supplemental Figure 1A (supplemental material available online with this article; doi:10.1172/JCI39199DS1), more
than 80% of the activated cells are lost during the first 3 weeks
of cytokine withdrawal. However, the remaining viable cells have
greatly improved survival (see below).
Activated primary T cells die quickly in culture without trophic
cytokines (29). Therefore, only Bcl-2–transduced cells survive
under the above culture conditions. Bcl-2 was overexpressed in the
vast majority of viable cells present after 4 weeks of culture (Figure 1C). In control experiments, cells transduced with the control
lentiviral vector that did not express Bcl-2 died within 2 weeks. To
further confirm the longevity of the Bcl-2–transduced cells and
the stability of Bcl-2 expression, we quantified viability and Bcl-2
expression weekly in cultures of isolated Bcl-2–transduced cells
maintained without supplemental cytokines. We found less than
20% cell loss (Supplemental Figure 1B) and stable Bcl-2 expression
(Supplemental Figure 1C) over a 4-week follow-up period.
Bcl-2–transduced cells reach a quiescent state similar to that of freshly
isolated primary resting CD4+ T cells. Because resting memory CD4+
T cells are a major reservoir for latent HIV-1 in vivo, an in vitro
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Figure 2
Characterization of resting Bcl-2–transduced cells. (A) Flow cytometric measurement of cell size. The forward scatter profile of Bcl-2–transduced cells coincided with that of freshly isolated resting CD4+ T cells. (B) Cell-cycle analysis in resting and activated freshly isolated CD4+ T
cells, Bcl-2–transduced cells, and latently infected Bcl-2–transduced cells. Data are plotted with DNA staining (Hoechst 33342) on the y axis
versus RNA staining (pyronin Y) on the x axis. Cells were either left in a resting state or activated with anti-CD3 and anti-CD28 antibodies for 2
days. The percentage of cells in each quadrant is indicated. (C) The expression of the activation markers CD25, CD69, and HLA-DR on resting
and activated Bcl-2–transduced cells. The percentage of cells in each quadrant is indicated. (D) Levels of IL-2 and IFN-γ mRNA in resting and
activated freshly isolated and Bcl-2–transduced CD4+ T cells. The levels of IL-2 and IFN-γ mRNA were quantified using real-time RT-PCR and
normalized to the ubiquitin mRNA levels. The fold change was relative to that observed in the freshly isolated resting CD4+ T cells. (E) Levels
of nuclear NF-κB p65 in resting and activated freshly isolated and Bcl-2–transduced CD4+ T cells. The nuclear NF-κB p65 was quantified by an
ELISA-based assay and normalized to the total protein concentration of each nuclear extract. Results shown are relative OD450 values. Data in
D and E are mean ± SD of triplicate samples from 1 of 2 independent experiments, all of which produced similar results.

latency model should consist of infected cells in a similarly quiescent state. After 4 weeks in culture without TCR stimulation
or cytokines, surviving Bcl-2–transduced cells were characterized
with regard to properties unique to primary resting T cells. These
include small cell size, absence of cell proliferation and cytokine
production, and lack of activation markers.
Resting Bcl-2–transduced cells exhibited small cell size (Figure 2A) and scanty cytoplasm (Supplemental Figure 2A). Using
DNA/RNA staining (39–41), we found that the majority of resting Bcl-2–transduced cells were in the G0/G1a phase of the cell
cycle, as is the case with freshly isolated primary resting CD4+ T
cells (Figure 2B). Both cell populations readily entered the cell
cycle following activation with anti-CD3 and anti-CD28 (Figure
2B). Surface expression of classic T cell activation markers such
The Journal of Clinical Investigation

as CD25, CD69, and HLA-DR was very low on resting Bcl-2–
transduced CD4+ T cells (Figure 2C). Less than 5% of these cells
expressed CD25, and expression of HLA-DR was similarly low.
Approximately 15%–20% of these cells had low but detectable levels of CD69. However, following 3 days of activation by anti-CD3
and anti-CD28, more than 90% of cells expressed high levels of
CD25 and CD69 and more than 25% of cells expressed HLA-DR
(Figure 2C). The resting status of the Bcl-2–transduced CD4+ T
cells was further confirmed by measurement of cytokine mRNA
levels using real-time RT-PCR (Figure 2D). Both the IL-2 and
IFN-γ transcripts were present only at very low levels in the resting Bcl-2–transduced cells, while transcript levels were increased
8-fold and 90-fold, respectively, following activation by anti-CD3
and anti-CD28.
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Figure 3
Resting Bcl-2–transduced cells exhibit resistance to HIV-1 infection and phenotypes of TEM. (A) Susceptibility of resting and activated freshly isolated and Bcl-2–transduced CD4+ cells to HIV-1 infection. Cells were infected with reporter virus pNL4-3-Δ6-drEGFP pseudotyped with HIV-1–X4
envelope. The number in each plot indicates the percentage of infected (GFP-positive) cells. (B) The expression of CD45RA, CD45RO, CCR7,
and CD62L on resting Bcl-2–transduced cells. The percentage of cells in each quadrant is indicated.

The host transcription factor NF-κB is critical for HIV-1 replication (14–16, 42). Lack of NF-κB activation in resting CD4+ T
cells is a major factor in HIV-1 latency (43). We therefore examined
the activation state of NF-κB in resting Bcl-2–transduced cells by
ELISA measurement of the nuclear levels of NF-κB p65. As Bcl-2–
transduced cells returned to a quiescent state, nuclear levels of
NF-κB fell to below those seen in freshly isolated resting CD4+ T
cells (Figure 2E). Upon stimulation with anti-CD3 and anti-CD28,
nuclear NF-κB was readily induced to high levels equivalent to
those of activated primary CD4+ T cells (Figure 2E).
An additional characteristic of resting CD4+ T cells is their
resistance to productive HIV-1 infection. Using a recombinant
HIV-1 vector capable of expressing GFP, we showed that resting
Bcl-2–transduced CD4+ T cells were resistant to HIV-1 infection
regardless of whether the viruses were pseudotyped with an X4
HIV-1 envelope (Figure 3A) or VSV-G (Supplemental Figure 2B).
However, T cell activation overcame this resistance (Figure 3A and
Supplemental Figure 2B). Taken together, the above data demonstrate that the Bcl-2–transduced cells reach a resting state similar
to that of primary resting CD4+ T cells while retaining the capability to be fully activated.
Because latent HIV-1 primarily resides in memory CD4+ T cells
(44), we further characterized Bcl-2–transduced cells for expression of memory T cell markers. Memory T cells are CD45RO positive. Central memory T cells (TCM) constitutively express CCR7
and CD62L, while effector memory T cells (TEM) show heterogeneous expression of CD62L but not CCR7 (45). A large portion
of Bcl-2–transduced cells (~85%) expressed CD45RO (Figure 3B).
Interestingly, approximately 30% of cells expressed both CD45RA
and CD45RO. Only a few cells (~6.5%) expressed CCR7. Therefore,
we concluded that resting Bcl-2–transduced cells are more like
TEM than TCM. Of note, a recent study reported that CD4+ TCM and
transition memory T cells (TTM) are 2 major cellular reservoirs for
HIV-1 in vivo (46). Determining whether the latently infected cells
generated in our model exhibit properties similar to those of TTM
cells requires further investigation
3476
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Establishment of HIV-1 latency in Bcl-2–transduced resting CD4+ T cells.
Latently infected cells are rare in vivo (47) because most infected
cells die from viral cytopathic effects or host cytolytic responses before they can revert to a resting state in which HIV-1 gene
expression is shut off. Preliminary results confirmed the previously reported cytopathic effects of HIV-1 gene products (48, 49). To
increase the efficiency with which HIV-1 latency was established,
we mutated the gag, vif, vpr, vpu, and nef genes of the reference
strain NL4-3. Point mutations were introduced to produce premature stop codons in each gene except for nef, which was truncated (Figure 4A). Our primary goal was to study the reactivation
of latent HIV-1, and thus the rev and tat genes were left unchanged
because their products are crucial for the expression of viral genes.
To keep splicing sites intact and mimic the processing of viral
transcripts, the overall genome structure of HIV-1 was preserved.
Destabilized EGFP was introduced to track the viral infection.
Compared with NL4-3, this modified viral vector, pNL4-3-Δ6drEGFP, gave dramatically improved viability of infected Bcl-2–
transduced cells. As shown below, this approach made it possible
to obtain large numbers of latently infected primary resting CD4+
T cells that could be used to study upregulation of HIV-1 gene
expression. The ultimate yield of latently infected cells was much
lower (approximately 5- to 10-fold) when Bcl-2–transduced cells
were infected with an HIV-1 construct in which all the reading
frames except env were open. For this reason, subsequent experiments were performed with the NL4-3Δ6-drEGFP virus.
To establish HIV-1 latency, Bcl-2–transduced cells were activated
and then infected with pseudotyped NL4-3-Δ6-drEGFP. Because
the env gene is disrupted by insertion of EGFP, an X4 envelope
was provided in trans to achieve single-round infection. The infection rate, based on the percentage of GFP+ cells 3 days after infection, was 5% to 10%. Following more than 4 weeks of culture in the
absence of cytokines and other activating stimuli, approximately
20%–30% of cells that initially expressed GFP became GFP negative.
We then isolated the GFP-negative cells by sorting. To determine
whether latency had been established, the GFP-negative cells were

http://www.jci.org

Volume 119

Number 11

November 2009

technical advance

Figure 4
Establishment of in vitro HIV-1 latency in resting Bcl-2–transduced CD4+ T cells. (A) Genome structure of the reporter virus NL4-3-Δ6-drEGFP.
It contains a truncated nef and premature stop codons in the ORFs of gag, vif, vpr, and vpu that alter the indicated amino acids shown in the
standard single-letter code. A portion of env was replaced with destabilized EGFP, and the signal peptide of env was mutated to allow the
destabilized EGFP to remain in the cytoplasm. The red letters indicate the mutated amino acids in the signal peptide. (B) Strategy for generating
latently infected Bcl-2–transduced cells. (C) Detection of latently infected cells in the sorted GFP-negative population. The sorted GFP-negative
cells were activated with anti-CD3 and anti-CD28 or PMA for 2 days and then analyzed by flow cytometry to quantify the number of GFP-positive
cells. FL2-H, red fluorescence channel. (D) Latently infected cells contain integrated viral genomes. Latently infected Bcl-2–transduced cells
were left untreated (upper panel) or were pretreated with either medium alone (middle panel) or 1 μM raltegravir (lower panel) for 1 day and
then activated with anti-CD3 and anti-CD28 monoclonal antibodies for 2 days. Cells were analyzed using flow cytometry. (E) Cell-cycle status
of latently infected cells was determined using Hoechst 33342/pyronin Y staining for DNA/RNA. The controls for the resting and activated cells
are the same as in Figure 2B. The percentage of cells in each quadrant is indicated.
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Figure 5
Response of latently infected Bcl-2–transduced
CD4+ T cells to small molecules and cytokines
known to reactivate latent HIV-1. Latently infected, Bcl-2–transduced cells were treated with
known small-molecule activators (A) or cytokines
(B). Bars represent the percentage of GFP-positive cells normalized to the response to anti-CD3
plus anti-CD28 antibodies. Data are mean ± SD of
triplicate samples from 1 of 2 independent experiments. The concentrations of small molecules
and cytokines used for the experiments are as follows: phytohemagglutinin (PHA) (1 μg/ml), PMA
(10 ng/ml), ionomycin (1 μM), prostratin (1 μM),
DPP (1 μM), TsA (200 nM), VA (5 mM), HMBA
(5 mM), IL-2 (100 U/ml), IL-1b (5 ng/ml), IL-4
(3 ng/ml), IL-6 (5 ng/ml), TNF-α (10 ng/ml), IL-7
(10 ng/ml), and IL-12 (10 ng/ml). For a positive
control, cells were activated with 2.5 μg/ml antiCD3 and 1 μg/ml anti-CD28.

activated and analyzed for GFP expression by flow cytometry. Of
the sorted GFP-negative cells, 1% to 3% could be induced to express
GFP by activating stimuli such as anti-CD3 plus anti-CD28 or
PMA (Figure 4, B and C). In control infected cultures that were
not stimulated, the fraction of GFP-positive cells remained less
than 0.2%. Taken together, these results indicate that latent infection was established in this system. We could further increase the
frequency of latently infected cells by enriching the GFP-positive
cells via sorting following the initial infection (Supplemental Figure 3A). The frequency of latently infected cells using this strategy
could reach 15%–50% (Supplemental Figure 3, A and B). Although
this enrichment increased the frequency of latently infected cells,
it did not increase their absolute number. Our preliminary data
showed that populations containing 1%–3% latently infected cells
generated without enrichment were adequate for high-throughput
screening. We therefore performed subsequent experiments without enrichment (Figure 4B).
An important feature of the stable reservoir for HIV-1 in vivo
is that the viral genome is integrated into a host-cell chromosome (27, 47). To prove that the latently infected cells generated
in this system contain an integrated form of the viral genome, we
activated the cells in the presence of an HIV-1 integrase inhibitor,
raltegravir. The concentration used was sufficient to block 99% of
integration events (50). Raltegravir did not block the reactivation
of latent HIV-1 (Figure 4D). This result confirms that this in vitro
system is a model for postintegration latency.
3478
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Even after prolonged culture in the absence of activating stimuli, a small fraction of GFP-negative cells still expressed low levels of activation markers such as CD25, CD69, and HLA-DR. To
exclude the possibility that latent HIV-1 might reside in the cells
with some extent of activation, we removed these CD25+, CD69+,
or HLA-DR+ cells by negative depletion. A very similar frequency
of cells with inducible GFP expression was found in the CD25–
CD69–HLA-DR– cells, excluding the possibility that latent HIV-1
resided in the cells with low levels of activation. We also evaluated the cell-cycle status of latently infected cells using DNA/RNA
staining. As shown in Figure 4E, the majority of latently infected
cells were in G0/G1a phase. Taken together, these observations
demonstrate the establishment of HIV-1 latency in vitro in resting Bcl-2–transduced primary CD4+ T cells.
To investigate whether there was any residual integrated provirus
that did not respond to T cell activation signals in this system, we
sorted the GFP– cells following activation of latently infected cells
by anti-CD3 and anti-CD28 for 3 days. The frequency of cells with
proviral DNA among the GFP– cells determined using real-time
PCR was similar to the percentage of GFP+ cells following activation. This suggests that approximately 50% of integrated proviruses were unresponsive to T cell activation (refer to Supplemental
Material for details). Whether these viruses can be reactivated by
subsequent rounds of activation requires future exploration.
The signaling pathways leading to the reactivation of latent HIV-1 remain
intact in this in vitro model. To validate that the signaling pathways
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Figure 6
Screening of small-molecule libraries identifies 5HN as a candidate activator. (A) Summary of screening results from JHDL. The
results were expressed as the percentage
of GFP-positive cells after normalization to
the response to anti-CD3 plus anti-CD28.
For simplicity, only 500 drugs including the
hits PMA and 5HN are shown. (B) Chemical
structure of 5HN. (C) Effects of 5HN, PMA,
and anti-CD3 plus anti-CD28 on the size of
latently infected resting CD4+ T cells. Cell
size was measured by flow cytometry using
the forward scatter. (D) Effect of 5HN on
the transcription of HIV-1. Latently infected
Bcl-2–transduced cells were left unstimulated or were stimulated with the indicated
concentrations of 5HN or anti-CD3 plus antiCD28 antibodies. The levels of viral mRNA
were quantified using real-time RT-PCR
and were normalized to the β-actin mRNA
levels. The fold change is shown relative to
that observed in the unstimulated samples.
Data are mean ± SD of triplicate samples
from 1 of 2 independent experiments, all of
which produced similar results.

known to induce reactivation of latent HIV-1 remain intact in
this in vitro model, we tested known HIV-1 activators, including
TCR agonists, mitogens, cytokines, and small molecules alone or
in combination. Representative flow cytometry plots are shown in
Supplemental Figure 4, A and B. The results are summarized in Figure 5, A and B. PMA, prostratin, and 12-deoxyphorbol 13-phenylacetate (DPP), known activators of PKC, all strongly activated latent
HIV-1. Ionomycin, an activator of nuclear factor of activated T cells
(NFAT), reactivated a smaller fraction of latent HIV-1. Interestingly,
valproic acid (VA), a known histone deacetylase (HDAC) inhibitor
and HIV-1 activator (13), barely activated latent virus, even at concentrations as high as 5 mM. However, trichostatin A (TsA), a more
potent HDAC inhibitor, activated a greater fraction of the cells at
a concentration of 200 nM. Hexamethylene bisacetamide (HMBA),
which activates latent HIV-1 in some cell line systems through regulation of active and inactive forms of positive transcription elongation factor b (pTEFb) (51, 52), only caused slight activation of
latent HIV-1 at a concentration of 5 mM in our assay.
We also tested some cytokines that are known to activate latent
HIV-1 (12, 53). Cytokines were used at concentrations previously
reported to induce activation of latent HIV-1 in various primary
cell systems. IL-7 alone strongly induced reactivation of latent
HIV-1 as previously reported (12, 32), while TNF-α, a well-known
activator of latent HIV-1 in transformed T cell lines (16, 21), activated only a small fraction of latent virus (Figure 5B). Consistent
with this observation, previous studies using the resting CD4+
T cells isolated from patients on HAART also revealed the low
activity of TNF- α in reactivation of latent HIV-1 (53). However,
a combination of IL-2, IL-6, and TNF-α dramatically increased
the reactivation of latent HIV-1 in our system. This response is
also similar to that reported in resting CD4+ T cells isolated from
patients on HAART (53).
Overall, the responses of the latently infected cells generated in
this system to known activators were very similar to those previously reported in other primary cell systems or in resting CD4+
The Journal of Clinical Investigation

T cells isolated from patients on HAART (10, 12, 53, 54). These
results strongly suggest that this in vitro HIV-1 latency model can
mimic the latently infected CD4+ T cells present in vivo.
Screening of small-molecule libraries for compounds that reactivate latent
HIV-1. Using the system described above, we screened a library of
2000 drugs and natural products and another set of more than
2400 compounds from the Johns Hopkins Drug Library (JHDL)
(55). Representative results are shown in Figure 6A. In total, 9 and
8 compounds that could activate latent HIV-1 were discovered in
the former and latter libraries, respectively. For further study, we
selected 1 of these compounds, 5-hydroxynaphthalene-1,4-dione
(5HN), because it was detected in both libraries and displayed the
highest capacity to reactivate latent HIV-1. 5HN is a natural quinone (Figure 6B) found in the leaves, roots, and bark of the black
walnut tree. 5HN was comparable to the combination of anti-CD3
and anti-CD28 antibodies in its ability to reactivate latent HIV-1
(Figure 6A and Supplemental Figure 5A).
To confirm the effect of 5HN on latent HIV-1, we used real-time
RT-PCR to examine levels of HIV-1 transcripts before and after
stimulation with 5HN. Viral transcription was induced up to
8.8-fold in a dose-dependent manner by 5HN (Figure 6C). The ED50
of 5HN in reactivating latent HIV-1 was 0.5 μM (Supplemental
Figure 5B), while the LD50 measurements for freshly isolated and
Bcl-2–transduced primary CD4+ T cells were 9.9 μM and 7.7 μM,
respectively (Supplemental Figure 5C). These results indicate the
narrow therapeutic range of 5HN.
We also examined the effect of 5HN in a transformed cell line
model of HIV-1 latency, the J-Lat system (22). We measured the
expression of viral marker GFP and viral transcripts. 5HN also
strongly activated latent HIV-1 in J-Lat cells (Supplemental Figure
6, A and B). Interestingly, although the potency of 5HN to reactivate latent HIV-1 was comparable to that of PMA in our primary
cell model, 5HN was less effective than PMA in J-Lat cells. These
results highlight the importance of using primary cells to screen
for compounds that target latent HIV-1.
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Figure 7
5HN does not activate CD4+ T cells. (A) Effects of 5HN on the expression of activation markers in primary resting CD4+ T cells. Freshly isolated
CD4+ T cells were treated with the indicated concentrations of 5HN or with anti-CD3 plus anti-CD28 antibodies for 3 days. Expression of activation markers was quantified by flow cytometry. The values indicated the percentage of cells expressing individual markers. Data are mean ± SD
of triplicate samples from 1 of 2 independent experiments. (B) Effects of 5HN on transcription of IL-2 and IFN-γ genes. Resting Bcl-2–transduced
CD4+ T cells were left unstimulated or were stimulated with 5HN or anti-CD3/anti-CD28. Levels of IL-2 and IFN-γ transcripts in total cellular RNA
were quantified by real-time RT-PCR and normalized to β-actin mRNA levels. The fold change relative to unstimulated samples is shown. Data
are mean ± SD of triplicate samples from 1 of 2 independent experiments. (C) Effect of 5HN on the susceptibility of freshly isolated resting CD4+
T cells to HIV-1 infection. Cells were incubated with medium alone, 5HN, or anti-CD3/anti-CD28 antibodies for 3 days and were then infected
with reporter virus NL4-3-ΔE-GFP. The number in each plot indicates the percentage of GFP-positive cells quantified by flow cytometry. (D) The
effects of 5HN on the proliferation of latently infected cells. Cell proliferation was determined using Hoechst 33342/pyronin Y staining for DNA/
RNA. The controls for the resting and activated cells are the same as in Figure 2B. The percentage of cells in each quadrant is indicated.

5HN does not cause global T cell activation. Agents that induce latent
HIV-1 by causing global T cell activation are likely to be too toxic
for clinical use. Therefore, we determined whether 5HN activates
T cells. Unlike cells stimulated with PMA or anti-CD3 and antiCD28 antibodies, the 5HN-treated latently infected cells retained
the same small size as untreated cells as determined by flow cytometric analysis (Figure 6D). We further showed that 5HN does
not cause upregulation of classic T cell activation markers such as
CD69, CD25, or HLA-DR on freshly isolated resting CD4+ T cells
(Figure 7A). Since the toxicity induced by T cell–activating agents
is likely to be due to cytokine release, we determined whether 5HN
induced production of T cell cytokines. IL-2 expression was not
induced by 5HN, while IFN-γ transcripts were upregulated by
approximately 10-fold. However, this level of IFN-γ activation is
much less than that induced by costimulation with anti-CD3 and
anti-CD28, which caused a greater than 1000-fold upregulation
(Figure 7B). Importantly, at concentrations that induce reactivation of latent HIV-1, 5HN did not render uninfected resting CD4+
3480
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T cells susceptible to HIV-1 infection (Figure 7C). Finally, 5HN did
not stimulate the proliferation of CD4+ T cells. This was evidenced
by measurement of DNA/RNA staining (Figure 7D) or the dilution of CFSE in the 5HN-treated cells (Supplemental Figure 7).
The above results demonstrate that 5HN did not cause global T
cell activation at concentrations that activated latent HIV-1.
ROS are involved in the reactivation of latent HIV-1 by 5HN. 5HN is a
quinone that can be reduced to a semiquinone radical by enzymes
such as NADPH oxidoreductase. Under aerobic conditions, the
semiquinone radical then generates superoxide anion (O2–) and
hydrogen peroxide (H2O2), which induce oxidative stress (56,
57). Because ROS can indirectly activate the host transcription
factor NF-κB that can in turn activate latent HIV-1 (58, 59), we
hypothesized that induction of oxidative stress by 5HN may play
a role in the reactivation of latent virus. To test this hypothesis,
we first assessed the effects of 5HN on the production of ROS in
freshly isolated primary resting CD4+ T cells using dihydrorhodamine 123 (DHR123). DHR123, a nonfluorogenic dye, is oxidized
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Figure 8
5HN activates latent HIV-1 via ROS and NF-κB. (A) ROS generation in primary resting CD4+ T cells. Cells were incubated with DHR123 prior
to 5HN treatment. DHR123 conversion, an indicator of intracellular ROS, was evaluated by flow cytometry. (B) 5HN activates NF-κB in primary
CD4+ T cells. Cells were left untreated, treated with 5HN, or stimulated with anti-CD3/anti-CD28 antibodies. The nuclear NF-κB p65 was quantified and normalized to the total protein concentration of each sample. Results are relative OD450 values. (C) Effects of 5HN on IκBα transcription.
Freshly isolated CD4+ T cells were left unstimulated or were stimulated with 5HN for different periods of time. IκBα transcripts in total cellular
RNA were quantified by real-time RT-PCR and normalized to β-actin mRNA levels. The fold change is relative to unstimulated samples. (D)
Antioxidants NAC and PDTC block 5HN reactivation of latent HIV-1. Latently infected cells were treated with NAC or PDTC 1 hour prior to 5HN
treatment. The percentage of the GFP-positive cells was measured using flow cytometry and normalized to that of cells receiving 5HN without
prior treatment. (E) NF-κB is involved in the reactivation of latent HIV-1 by 5HN. Bcl-2–transduced cells latently infected with NL4-3-Δ6-drEGFP
or mκ2-NL4-3-Δ6-drEGFP were treated with 5HN. GFP-positive cells were measured using flow cytometry and normalized to the maximal percentage of GFP-positive cells in each population following treatment with PMA plus ionomycin. Data in B–E are mean ± SD of triplicate samples
from 1 of 2 independent experiments, all of which produced similar results.

intracellularly by ROS into the fluorescent dye rhodamine 123
(60). Production of ROS in primary CD4+ T cells was detected
within 2 hours of addition of concentrations of 5HN known to
reactivate latent HIV-1 (Figure 8A). Because ROS can indirectly
activate NF-κB, we next assessed the activation of NF-κB by measuring the nuclear levels of NF-κB using an ELISA-based assay.
5HN activated NF-κB in a dose-dependent manner (Figure 8B).
To ensure that 5HN activates NF-κB in primary CD4+ T cells,
we also quantified the transcripts of IκBα, an NF-κB–responsive
gene, and showed that 5HN stimulates the expression of IκBα
(Figure 8C). Antioxidants like N-acetylcysteine (NAC) or pyrrolidine dithiocarbamate (PDTC) suppress the effects of ROS on
the activation of NF-κB (59). Consistent with this observation,
preincubation of the latently infected cells with NAC or PDTC
dramatically suppressed the stimulatory effect of 5HN on the
expression of latent HIV-1 (Figure 8D). This result supports the
role of ROS in the activation of latent HIV-1 by 5HN.
To further confirm that NF-κB is required for the activation of
latent HIV-1 by 5HN, we mutated the 2 tandem NF-κB–binding
sites in the enhancer region of 3′ LTR of pNL4-3-Δ6-drEGFP
The Journal of Clinical Investigation

(mκ2-LTR- NL4-3-Δ6-drEGFP). Following reverse transcription
and integration into the genome of infected cells, the 5′ LTR of
integrated reporter virus is derived from the 3′ LTR that contains mutated NF-κB–binding sites (61). The response to 5HN
in the cells latently infected with mκ2-LTR NL4-3-Δ6-drEGFP
was much lower than that in cells infected with wild-type NL43-Δ6-drEGFP (Figure 8E), indicating the essential role of NF-κB
in the signaling pathways downstream of 5HN. Interestingly, at
higher concentrations of 5HN (5 μM), there was partial activation of the mκ2-LTR NL4-3-Δ6-drEGFP reporter virus, suggesting the possibility of NF-κB–independent pathways for the reactivation of latent HIV-1 by 5HN.
PKCθ is a master regulator in TCR signaling pathways (62). Activation of PKC leads to activation of key transcription factors in the
immune response, including NF-κB and activator protein 1 (AP-1).
Because 5HN activates latent HIV-1 via NF-κB, we determined whether the effects of 5HN depend on PKC. Using the pan PKC inhibitor
Gö6983, we found that inhibition of PKC completely suppressed
PMA-induced activation of latent HIV-1 and reduced by approximately 50% the response to anti-CD3 and anti-CD28 costimulation.
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Figure 9
5HN activates latent HIV-1 independent of PKC and NFAT. (A) Effect of a PKC inhibitor on the reactivation of latent HIV-1 by 5HN. Latently
infected Bcl-2–transduced cells were incubated with PKC inhibitor Gö6983 1 hour prior to the treatment with each activator. Cells were collected
and analyzed for GFP-positive cells after 2 days of incubation. The results were normalized to the effect of anti-CD3 plus anti-CD28 costimulation. Data are mean ± SD of triplicate samples from 1 of 2 independent experiments, all of which produced similar results. (B) Effect of CsA on
the reactivation of latent HIV-1 by 5HN. Latently infected Bcl-2–transduced cells were incubated with CsA 1 hour prior to the treatment with each
activator. Cells were collected and analyzed for GFP-positive cells after 2 days of incubation. The results were normalized to the effect of PMA
treatment. Data are mean ± SD of triplicate samples from 1 of 3 independent experiments.

However, it almost had no effect on the activation of latent HIV-1 by
5HN. This suggests that 5HN acts downstream of PKC in the NF-κB
signaling pathway leading to the activation of latent HIV-1 (Figure
9A). NFAT, another essential transcription factor for T cell activation,
is also known to promote HIV-1 gene expression (63). To exclude the
possibility that NFAT plays a role downstream of 5HN, we showed
that cyclosporin A (CsA), an inhibitor of the NFAT signaling pathway, does not suppress the effect of 5HN on the reactivation of latent
HIV-1, while it inhibits the effect of ionomycin (Figure 9B).
5HN is also known to inhibit Pin1, a peptidyl-prolyl isomerase
that plays an important role in transcription regulation (64, 65).
To determine whether inhibition of Pin1 is involved in reactivation
of latent HIV-1, we knocked down Pin1 expression in the latently
infected Bcl-2–transduced cells using Pin1-specific RNAi. Downregulation of Pin1 did not activate latent HIV-1 (data now shown).
We also demonstrated that fredericamycin A, a Pin1 inhibitor (66),
failed to induce latent HIV-1 in our in vitro primary cell model
(data not shown). Together, these results suggest that inhibition of
Pin1 by 5HN is not responsible for reactivation of latent HIV-1.
Discussion
The latent reservoir for HIV-1 in resting memory CD4+ T cells
remains a major barrier to virus eradication. The lack of a convenient in vitro latency model in primary resting CD4+ T cells has
hampered progress in exploring ways to overcome HIV-1 latency. In
this study, we took advantage of the genetically modified primary
CD4+ T cells to establish an in vitro HIV-1 latency system. We demonstrated that Bcl-2–transduced cells can reach a profoundly quiescent state in which HIV-1 latency can be established. More importantly, using this model, we performed small-molecule screening
and identified 5HN as an activator of latent HIV-1 that, unlike previously described activators, does not induce global T cell activation. These results illustrate the application of this approach to the
discovery of novel agents for the eradication of latent HIV-1.
Overexpression of Bcl-2 allows the primary CD4+ T cells to survive in a quiescent state, a key step to establishing HIV-1 latency in
vitro. Although overexpression of Bcl-2 may alter the physiology of
3482
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CD4+ T cells, our extensive analysis revealed that the Bcl-2–transduced cells are similar to freshly isolated CD4+ T cells in both the
activated and resting states. Bcl-2 is a downstream antiapoptotic
effector of IL-7, an essential cytokine in maintaining the survival of
resting naive and memory T cells in vivo. Prior studies have shown
that the Bcl-2 transgene can partly compensate for deprivation of
IL-7, indicating the important role of Bcl-2 in the homeostasis of
resting T cells (35, 36). Because IL-7 also activates latent HIV-1 (12,
32), decoupling Bcl-2 from other IL-7 signaling pathways provided
us an opportunity to measure the HIV-1 LTR activity in cells that
are in a profoundly quiescent state.
Another concern is that a modified HIV-1 vector was used instead
of wild-type virus. Although the modifications increased the yield
of latently infected cells, there is the possibility that modified HIV-1
may behave differently than wild-type virus. We have preserved portions of the HIV-1 sequence relevant to the regulation of viral gene
expression (LTR, tat, and rev). Therefore, this model is most useful
in studying the upregulation of HIV-1 gene expression in latently
infected cells, as we have done here. We have shown that the signaling pathways that lead to reactivation of latent HIV-1 are well preserved in this in vitro model. We tested an array of small molecules
and cytokines and observed responses very similar to those seen in
other primary cell models and latently infected CD4+ T cells from
patients on HAART (10, 12, 53, 54). This result justifies the use
of this model in investigating the reactivation of latent HIV-1. In
order to increase the yield of latently infected cells, we inactivated
genes whose products have been associated with cytopathicity. For
this reason, the model may not be ideal for studying the fate of
cells reactivated from latency or the efficiency with which latency
is established. Importantly, we have recently shown that latently
infected cells can be obtained using the same approach with a vector in which all of the HIV-1 ORFs except env are functional (L.
Shan et al., unpublished observations). However, as expected, the
yield of latently infected cells is substantially lower.
Although several in vitro HIV-1 latency models in primary CD4+
T cells have been described recently, certain factors limit their utility in high-throughput screening for activators of latent HIV-1.
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Several studies have demonstrated that HIV-1 can establish latency
by direct infection of resting CD4+ T cells in vitro (40, 67, 68). This
strategy does have some advantages because it avoids the activation of T cells and utilizes wild-type HIV-1. However, the efficiency
with which latency is established may be lower than that of the
activation-dependent pathway described here, and this system is
still subject to the short life span of resting CD4+ T cells in an in
vitro culture system. Bosque et al. infected activated CD4+ T cells
and maintained them in the presence of IL-2 (25). Because IL-2
also activates latent HIV-1, it is uncertain whether IL-2 disturbs
the quiescent state of these cells. Some models were created by
infection of thymocytes with HIV-1 (24, 69). However, the majority of the resulting cells were resting naive CD4+ T cells rather than
memory CD4+ T cells, which harbor latent HIV-1 in vivo. Marini
et al. used low doses of IL-7 to generate and maintain memory
CD4+ T cells in vitro up to 2 months and established viral latency among these cells (26). Although interesting, this model only
yields approximately 20% viable cells and therefore may not produce enough latently infected cells for high-throughput screening.
In addition, IL-7 can activate latent HIV-1 (12). This may also confound the results of studies examining the reactivation of latent
HIV-1 by other agents. Therefore, our primary cell HIV-1 latency
model is the only one in which cells are maintained in vitro in the
absence of activating cytokines.
The system described here can serve as an efficient platform to
screen for activators of latent HIV-1 that do not induce global T
cell activation. Bcl-2 transduction allows us to generate sufficient
numbers of latently infected cells for high-throughput screening.
In addition, the resting phenotype of the resulting cells recapitulates the quiescent state of primary resting CD4+ T cells. By flow
cytometry analysis, we can easily detect changes in parameters that
measure T cell activation, for instance, cell size. We illustrated the
potential application of this in vitro system by identifying 5HN
as an activator of latent HIV-1 that does not induce global T cell
activation. 5HN can strongly reactivate latent HIV-1 with an efficiency similar to that of TCR stimulants. High reactivation efficiency is essential for eradicating HIV-1 because even a small number of viruses released from any residual latently infected cells can
rebound exponentially after discontinuation of HAART.
Our data suggest that 5HN activates latent HIV-1 through the
ROS and NF- κB signaling pathways. The role of ROS in the activation of NF-κB was first described by Schreck et al. (59). Some
investigators have proposed a central role for ROS in mediating
the ability of extrinsic stimuli to activate NF-κB, although even
after more than a decade of studies, there is still uncertainty about
the target protein that senses ROS and transduces the signals to
activate NF-κB (58). The potential toxicity of ROS also creates
concern about the therapeutic application of 5HN. Previous studies revealed differential cellular responses to the different levels of
ROS. In response to low levels of ROS, cells upregulate the antioxidant genes, while high levels of ROS induce apoptosis. Interestingly, intermediate levels can stimulate some inflammatory genes,
such as NF-κB and AP-1 (58). This may explain why 5HN has a
narrow therapeutic window. In addition, 5HN is chemically reactive and affects several cellular proteins (70). Although we showed
that 5HN activates latent HIV-1 independent of Pin1, it is possible
that other mechanisms are involved. Further studies are required
to determine whether we can decouple the toxicity of 5HN from its
ability to activate latent HIV-1. One intriguing finding is that 5HN
activates latent HIV-1 without causing nonspecific T cell activaThe Journal of Clinical Investigation

tion. Given that NF-κB is a key transcription factor in controlling
innate and adaptive immunity, it is surprising that 5HN stimulates latent HIV-1 by activating NF-κB without inducing global T
cell activation. This can be explained by our observation that 5HN
activates latent HIV-1 independent of NFAT and PKCθ. PKCθ is a
master regulator of T cell activation and activates multiple signaling pathways, including the NF-κB, AP-1, and ERK1/2 pathways
(62). The importance of NFAT proteins in T cell activation is also
well documented (71). Bypassing PKCθ and NFAT may allow 5HN
to avoid full-blown T cell activation. This finding also suggests
that reactivation of latent HIV-1 does not necessarily require T cell
activation and that the pathways leading to the activation of latent
HIV-1 can be separated from those involving in T cell activation.
Because of the high cost and potential toxicities of long-term
HAART and the disappointing results from the clinical trials of
HIV-1 vaccines and microbicides (72, 73), there is still a pressing
need for pursuing the goal of eradication. To cure HIV-1 infection is exceptionally challenging and will likely require combining
HAART with agents that can purge latent virus. The identification of 5HN not only expands the number of classes of latencyreversing agents but also demonstrates the possibility of utilizing pathway(s) further downstream of TCR stimulation to avoid
global T cell activation. Although the toxicities of 5HN raise concerns for its clinical application, this is a proof of concept for this
approach to finding novel strategies to reactivate latent HIV-1
without inducing global T cell activation.
Methods
Reagents and cell lines. Monoclonal anti-CD3 (catalog no. 555336) and antiCD28 (catalog no. 555725) antibodies were from BD Biosciences. VA, HMBA,
PMA, 5HN, NAC, TsA, and DHR123 were from Sigma-Aldrich. Prostratin
and DPP were from LC Laboratories. IL-1b, IL-2, IL-4, IL-6, IL-7, IL-12, and
TNF-α were from R&D Systems. PDTC was from EMD. Fredericamycin A
was a gift from Ben Shen (University of Wisconsin Madison, Madison, Wisconsin, USA). J-Lat full-length clone 10.6 was obtained through NIH AIDS
Research and Reference Reagent Program (contributed by Eric Verdin).
5HN was dissolved in DMSO at a concentration of 10 mM and then was
aliquotted and stored at –20°C for up to 2 months.
Plasmids and vector construction. The lentiviral vector FURW was a gift from
Linzhao Cheng (Johns Hopkins University School of Medicine). Bcl-2 cDNA
was a gift from M. Hardwick (Johns Hopkins University School of Medicine).
To generate the Bcl-2 expression vector EB-FLV, Bcl-2 was first amplified by
PCR from cDNA using the primers containing the KpnI and EcoRI recognition sites and then subcloned downstream of EF1α promoter in the vector pEF1/Myc-His-A (Invitrogen). The DNA sequence containing the EF1α
promoter and Bcl-2 was then cloned into Zero-Blunt TOPO cloning vector
PCR4Blunt-TOPO (Invitrogen), verified by direct sequencing, and subsequently subcloned into FURW using the PacI and SalI restriction sites.
The reporter viral vector pNL4-3-Δ6-drEGFP was derived from the vector pNL4-3-ΔE-GFP, which contains an HIV-1 genome with a portion of
envelope replaced with EGFP (74). Instead of EGFP, pNL4-3-Δ6-drEGFP
contains destabilized EGFP, in which the PEST sequence cloned from
pzGreen-DR (Clontech) was ligated in frame to the 3′ end of EGFP. To
allow the destabilized EGFP to remain in the cytoplasm, the signal peptide
of the envelope in pNL4-3-Δ6-drEGFP was mutated using QuickChange
II XL site-directed mutagenesis kit (Stratagene) with primer pairs 5′GGGGCACCATGCGCCGTGGGACATCGATGATCTGTAGTG and 5′CACTACAGATCATCGATGTCCCACGGCGCATGGTGCCCC. Premature stop codons were introduced into the gag, vif, vpr, and vpu genes of
pNL4-3-Δ6-drEGFP sequentially using QuickChange II XL site-directed
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mutagenesis kit. The nucleotide positions and primer sequences used for
mutagenesis are shown in Supplemental Table 1. The nef gene was also
truncated. To generate pmκ2-LTR- NL4-3-Δ6-drEGFP, the tandem NFκB–binding sites (GGGACTTTCC) in the 3′ LTR of pNL4-3-Δ6-drEGFP
were both replaced with the sequence of CTCACTTTCC. All the mutations
were confirmed by sequencing. A packaging vector pC-Help (75) was a gift
from Jakob Reiser (Louisiana State University Health Sciences Center, New
Orleans, Louisiana, USA).
Virus stock production. The Bcl-2 lentiviral vectors were generated by
cotransfecting HEK293T cells with a plasmid encoding EB-FLV, VSV-G
envelope (pVSVG), and a packaging vector pC-Help using Lipofectamine
2000 (Invitrogen) following the manufacturer’s instructions. Supernatants were harvested after 72 hours, spun at 335 g, and filtered through
a 0.22-μm membrane to clear cell debris. Virus was pelleted at 100,000 g
with 10% volume of 20% sucrose in the bottom for 2 hours at 4°C. The
recombinant CXCR4-tropic HIV-1 pseudoviruses were generated by the
same procedure using a plasmid encoding the HIV-1 envelope (pCXCR4),
pC-Help, and pNL4-3-Δ6-drEGFP.
Cell culture and generation of latently HIV-1–infected Bcl-2–transduced cells.
This study was approved by the Johns Hopkins Institutional Review Board.
Healthy adult blood donors provided informed consent before enrollment.
Primary human CD4+ T cells were isolated from PBMCs using a Human
CD4+ T Cells Isolation Kit II (Miltenyi Biotec). To bind anti-CD3 antibodies to plates, 1 ml of antibodies in PBS at 10 μg/ml was incubated in each
well of a 6-well plate for 90 minutes at 37°C. Primary CD4+ T cells were
activated by incubation in these plates with 1 μg/ml anti-CD28 monoclonal antibody, 100 U/ml IL-2, and T cell growth factor–enriched medium.
On day 3, the activated CD4+ T cells were transduced with EB-FLV at the
MOI of 5 to 10 by spinoculation of cells at 1200 g at room temperature
for 2 hours. The transduced cells were cultured in IL-2 and T cell growth
factor–enriched medium for another 3 days, and the medium was replaced
with RPMI 1640 with 10% FBS and 1% penicillin/streptomycin without
supplemental cytokines. Following 3–4 weeks of culture in the absence of
exogenous cytokines, viable cells were isolated using Ficoll-Hypaque density gradient centrifugation.
To expand Bcl-2–transduced cells, we activated them with plate-bound
anti-CD3 antibody and soluble anti-CD28 antibody. We then added
100 U/ml IL-2 every other day for 10–12 days. Usually, the number of
cells increased to 5- to 10-fold. To generate latently HIV-1–infected,
Bcl-2–transduced cells, we infected activated Bcl-2–transduced cells
with reporter virus NL4-3-Δ6-drEGFP at an MOI of less than 0.1. We
maintained the infected cells in IL-2 and T cell growth factor–enriched
medium for 3 days after infection. We then incubated the infected cells
in the RPMI 1640 with 10% FBS and 1% penicillin/streptomycin without
exogenous cytokines for more than 1 month. Finally, we isolated the
GFP-negative cells to more than 99.9% purity using fluorescence-activated cell sorting.
RNA extraction and real-time RT-PCR. We isolated total cellular RNA
using RNeasy Mini Kit (QIAGEN). We performed RT reactions using
SuperScript III Reverse Transcriptase (Invitrogen) with random primers
(Invitrogen). IFN-γ and IL-2 transcripts were measured using TaqMan
Gene Expression Assays on an ABI 7300 Real-Time PCR System (Applied
Biosystems assays Hs00174143_ml and Hs00174114_ml, respectively).
For an internal control, ubiquitin transcripts (GenBank accession number M26880) were also measured by real-time RT-PCR with SYBR Green
PCR Master Mix (Applied Biosystems) and a pair of primers: 5′-ATTTGGGTCGCAGTTCTTG-3′ and 5′-TGCCTTGACATTCTCGATGGT-3′
(76). In the 5HN treatment experiment, β-actin was used as an internal
control because 5HN activates ubiquitin. β-actin was measured using
TaqMan Gene Expression Assay with the primers and probes of ACTB
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(part number 433762F). Control reactions with no template or without
reverse transcriptase were negative.
Measurement of NF-κB activation. Nuclear extracts were prepared using
a Nuclear Extract Kit (Active Motif) according to the manufacturer’s
instructions. Protein concentration of nuclear extract was determined
using DC-protein assay (Bio-Rad) following the manufacturer’s instructions. NF-κB activation was measured by the TransAM NF-κB p65
ELISA kit (catalog no. 40097; Active Motif). This kit provides a 96-well
plate with immobilized oligonucleotides containing the NF-κB–binding
sites (5′-GGGACTTTCA-3′) derived from HIV-1 LTR. Nuclear extract
was added to each well, and NF-κB that bound to the oligonucleotides
was detected by an NF-κB p65 antibody and a secondary antibody conjugated with HRP. The levels of NF-κB activation, as bound NF-κB p65,
were measured in triplicate on a Vmax kinetic microplate reader (Molecular Devices) at OD450.
Compound libraries. The compound libraries tested were The Spectrum Collection (MicroSource Discovery Inc.) and JHDL. The 2000
compounds in The Spectrum Collection consist of FDA-approved compounds, natural products, and other bioactive compounds. A list of the
compounds is available at the MicroSource Discovery website (www.
msdiscovery.com/spectrum.html). The compounds in JHDL are primarily FDA-approved compounds (55).
Measurement of the reactivation of latent HIV-1 from the latently infected Bcl-2–
transduced cells by activators. Fifty thousand latently infected cells were resuspended in 200 μl of medium (RPMI 1640 with 10% FBS and 1% penicillin/streptomycin) and were cultured in round-bottom 96-well plates. The
cells were then treated with the indicated concentrations of activators. As
a positive control, cells were treated with 2.5 μg/ml anti-CD3 and 1 μg/ml
anti-CD28 monoclonal antibodies. After 40–48 hours at 37°C, reactivation of latent HIV-1 was determined by quantifying the percentage of GFP+
cells using the standard mode of the High Throughput Sampler (HTS) in
FACSCalibur and analyzed using Plate Manager (BD Biosciences). The percentage of GFP+ cells was normalized based on the response to anti-CD3
plus anti-CD28 antibodies.
Screen of JHDL. For high-throughput screening, 2.5 × 104 latently infected cells were resuspended in 200 μl of medium in round-bottom 96-well
plates. Each compound was added at 10 μM. Each plate contained cells
treated with either 10 ng/ml PMA or 2.5 μg/ml anti-CD3 plus 1 μg/ml
anti-CD28 antibodies as positive controls. After 40–48 hours at 37°C, reactivation of latent HIV-1 was determined as above.
Detection of intracellular ROS. Primary CD4+ T cells isolated from healthy
donors or Bcl-2–transduced cells were resuspended in RPMI 1640 with 10%
FBS and 1% penicillin/streptomycin at 106 cells/ml. 5 × 105 cells/well in
500 μl medium were plated in 48-well plates. DHR123 was dissolved in
DMSO at a concentration of 10 mM and was stored at –20°C. Before assay,
stock solutions were diluted in PBS to 100 μM and added at the indicated
concentrations 30 minutes prior to 5HN treatment. Samples were collected
and analyzed at 30, 60, and 120 minutes after addition of 5HN. Conversion
of DHR123 to rhodamine 123 by ROS was quantified as increasing green
fluorescence using a FACSCalibur (BD Biosciences).
Measurement of intracellular HIV-1 transcripts. Total cellular RNA was isolated from 1 × 106 latently infected Bcl-2–transduced cells or 0.5 × 105
J-Lat cells using RNeasy Mini Kit (QIAGEN). mRNA was purified using
Dynabeads oligo (dT)25 beads (Invitrogen). The bound mRNA was used
directly for RT reactions using SuperScript III Reverse Transcriptase
(Invitrogen). HIV-1 transcripts were measured by real-time RT-PCR
with SYBR Green PCR Master Mix (Applied Biosystems) and the primer
pairs that detect single-spliced viral transcripts (5′-GGGTCTCTCTGGTTAGACCAGATCTGAGCC-3′, and 5′- CTCCGCTTCTTCCTGCCAT)
(77). For an internal control, β-actin was measured using a TaqMan Gene
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Expression Assay. Control reactions with no template or without the addition of RT were negative.
Statistics. Activation experiments were performed in triplicate cultures. Data are presented as the arithmetic mean ± SD for a representative experiment drawn from 2 or 3 experiments, all of which provided
similar results.
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